secwatch.observer — SEC 8-K summary
======================================

Issuer:     Instil Bio, Inc. (TIL)
CIK:        0001789769
Form:       8-K
Filed at:   2023-03-31T23:59:59+00:00
Accession:  0001789769-23-000033
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Instil Bio reports 2022 net loss of $223M; cash runway beyond 2026; ITIL-306 phase 1 in 2H 2023
--------------------------------------------------------------------------------

- Cash & marketable securities $260.9M (Dec 31, 2022) vs $454.1M in 2021; cash runway beyond 2026 with <$10M quarterly burn from 2H 2023.
- Net loss $223.2M in 2022 ($1.72/share) vs $156.8M ($1.48/share) in 2021; restructuring charge $23.2M.
- Discontinued ITIL-168 program Dec 2022 over manufacturing issues; prioritized ITIL-306 with anticipated UK MHRA CTA clearance 2H 2023.
- Initial ITIL-306 phase 1 clinical data expected in 2024; consolidated R&D ops to Manchester, UK; seeking lease/sale of Tarzana facility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789769/000178976923000033/0001789769-23-000033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789769/000178976923000033/til-20230331.htm
  HTML page:      https://secwatch.observer/filing/0001789769-23-000033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer